AI Engines For more Details: Perplexity Kagi Labs You
Psoriasis Treatment: Etretinate is indicated for the treatment of severe psoriasis, a chronic autoimmune skin condition characterized by thickened, red, and scaly patches of skin. It is typically prescribed when other treatments have failed to provide adequate relief.
Retinoid Action: Etretinate works by modulating the growth and differentiation of skin cells. It reduces the proliferation of skin cells (keratinocytes) and promotes their normal differentiation, leading to a decrease in the formation of psoriatic plaques.
Long Duration of Action: Etretinate has a long duration of action, which allows for less frequent dosing compared to some other psoriasis medications. This can improve treatment adherence and convenience for patients.
Side Effects: Despite its effectiveness, etretinate is associated with several potential side effects, some of which can be serious. Common side effects include dry skin, dry mouth, dry eyes, itching, and hair loss. It can also cause nail changes, such as thickening or brittleness. Other potential side effects include headache, fatigue, joint pain, and muscle pain.
Teratogenicity: Etretinate is highly teratogenic, meaning it can cause severe birth defects if taken during pregnancy. It has a long half-life, and even a single dose can remain in the body for an extended period. Due to this risk, etretinate is contraindicated in pregnant women and women of childbearing potential who are not using effective contraception. Additionally, women of childbearing age are advised to avoid becoming pregnant for several years after discontinuing etretinate therapy.
Monitoring: Patients taking etretinate require close monitoring by a healthcare provider to assess treatment response and monitor for potential side effects. Regular blood tests, including liver function tests and lipid profiles, may be recommended to monitor for adverse effects on the liver and lipid metabolism.
Sun Sensitivity: Etretinate can increase sensitivity to sunlight, so patients should take precautions to protect their skin from sun exposure, such as wearing protective clothing and using sunscreen.
Drug Interactions: Etretinate may interact with other medications, including certain antibiotics and oral contraceptives. Patients should inform their healthcare provider about all medications they are taking to avoid potential interactions.
Rank | Probiotic | Impact |
---|---|---|
species | Bifidobacterium adolescentis | Reduces |
species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 0.1 | -0.1 | |
ADHD | 1.4 | 0 | 0 |
Age-Related Macular Degeneration and Glaucoma | 0.4 | 0.1 | 3 |
Allergic Rhinitis (Hay Fever) | 0.9 | 0.2 | 3.5 |
Allergies | 1 | 1.3 | -0.3 |
Allergy to milk products | 0.8 | 0.3 | 1.67 |
Alzheimer's disease | 0.2 | 3.2 | -15 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.8 | 0.2 | 3 |
Ankylosing spondylitis | 1.1 | 0.4 | 1.75 |
Anorexia Nervosa | 0.1 | 1.6 | -15 |
Antiphospholipid syndrome (APS) | 1 | 1 | |
Asthma | 0.6 | 0.5 | 0.2 |
Atherosclerosis | 0.1 | 1.7 | -16 |
Atrial fibrillation | 1 | 1.1 | -0.1 |
Autism | 4.7 | 3.9 | 0.21 |
Barrett esophagus cancer | 0 | 0 | |
benign prostatic hyperplasia | 0.1 | 0.1 | |
Bipolar Disorder | 0.3 | 0.4 | -0.33 |
Brain Trauma | 0.1 | 0.5 | -4 |
Carcinoma | 0.4 | 0.3 | 0.33 |
Celiac Disease | 0.4 | 0.5 | -0.25 |
Cerebral Palsy | 0.6 | 0.5 | 0.2 |
Chronic Fatigue Syndrome | 1.2 | 0.7 | 0.71 |
Chronic Kidney Disease | 1.1 | 1.5 | -0.36 |
Chronic Lyme | 0.5 | -0.5 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.1 | 0.7 | -6 |
Chronic Urticaria (Hives) | 0.8 | 0.7 | 0.14 |
Coagulation / Micro clot triggering bacteria | 0.5 | 0.4 | 0.25 |
Colorectal Cancer | 1 | 0.4 | 1.5 |
Constipation | 0.5 | 0.4 | 0.25 |
Coronary artery disease | 0.5 | 0 | 0 |
COVID-19 | 1.8 | 4.4 | -1.44 |
Crohn's Disease | 1.9 | 2.3 | -0.21 |
cystic fibrosis | 0.3 | 0.5 | -0.67 |
deep vein thrombosis | 0.3 | 0.4 | -0.33 |
Depression | 2.5 | 2.8 | -0.12 |
Dermatomyositis | 0 | 0.1 | 0 |
Eczema | 0.2 | 0.6 | -2 |
Endometriosis | 0.6 | 0.3 | 1 |
Epilepsy | 0.3 | 0.5 | -0.67 |
Fibromyalgia | 1.3 | 1.8 | -0.38 |
Functional constipation / chronic idiopathic constipation | 2.2 | 2.5 | -0.14 |
gallstone disease (gsd) | 0.7 | 0.4 | 0.75 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.1 | 0 | 0 |
Generalized anxiety disorder | 0.4 | 0.7 | -0.75 |
giant cell arteritis | 0.5 | -0.5 | |
Glioblastoma | 0 | 0 | |
Gout | 0 | 0 | |
Graves' disease | 0.3 | 0.4 | -0.33 |
Halitosis | 0.1 | 0 | 0 |
Hashimoto's thyroiditis | 1.3 | 0.1 | 12 |
Hidradenitis Suppurativa | 0 | 0 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.5 | 0.6 | 1.5 |
hypercholesterolemia (High Cholesterol) | 0.5 | 0.5 | |
hyperglycemia | 0.1 | 0.3 | -2 |
Hyperlipidemia (High Blood Fats) | 0.1 | 0.1 | |
hypertension (High Blood Pressure | 0.4 | 0.7 | -0.75 |
Hypothyroidism | 0.1 | -0.1 | |
Hypoxia | 0.2 | 0.2 | |
IgA nephropathy (IgAN) | 2.2 | -2.2 | |
Inflammatory Bowel Disease | 0.6 | 4 | -5.67 |
Insomnia | 0.1 | 0.7 | -6 |
Intelligence | 0.9 | 0.7 | 0.29 |
Intracranial aneurysms | 0.2 | 0.2 | |
Irritable Bowel Syndrome | 1.3 | 1.4 | -0.08 |
Liver Cirrhosis | 1.3 | 1.1 | 0.18 |
Long COVID | 1.4 | 2 | -0.43 |
Low bone mineral density | 0.7 | -0.7 | |
Lung Cancer | 0.1 | 0.1 | |
ME/CFS with IBS | 0.5 | 0.2 | 1.5 |
ME/CFS without IBS | 0.7 | 0.1 | 6 |
Menopause | 0.1 | 0.1 | |
Metabolic Syndrome | 1.6 | 1.8 | -0.13 |
Mood Disorders | 3.5 | 2.8 | 0.25 |
multiple chemical sensitivity [MCS] | 0 | 0 | |
Multiple Sclerosis | 0.3 | 4.2 | -13 |
Multiple system atrophy (MSA) | 0.1 | 0.1 | 0 |
Neuropathy (all types) | 0 | 0.1 | 0 |
neuropsychiatric disorders (PANDAS, PANS) | 0.2 | 0.2 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.3 | 1.3 | 0 |
NonCeliac Gluten Sensitivity | 0.1 | -0.1 | |
Obesity | 2.2 | 0.3 | 6.33 |
obsessive-compulsive disorder | 2 | 2.1 | -0.05 |
Osteoarthritis | 0.8 | 0.8 | |
Osteoporosis | 0.7 | 0.1 | 6 |
pancreatic cancer | 0 | 0 | |
Parkinson's Disease | 0.5 | 2 | -3 |
Polycystic ovary syndrome | 0.9 | 0.9 | 0 |
Postural orthostatic tachycardia syndrome | 0.5 | 0.1 | 4 |
Premenstrual dysphoric disorder | 0.1 | 0.1 | 0 |
primary biliary cholangitis | 0.3 | -0.3 | |
Psoriasis | 0.8 | 1.3 | -0.63 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.9 | 1.1 | 0.73 |
Rosacea | 0.8 | 0.9 | -0.13 |
Schizophrenia | 2.5 | 1 | 1.5 |
scoliosis | 0 | 0.5 | 0 |
Sjögren syndrome | 1 | 1.1 | -0.1 |
Sleep Apnea | 0.1 | 0.5 | -4 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.2 | 0.2 | |
Stress / posttraumatic stress disorder | 1.3 | 0.6 | 1.17 |
Systemic Lupus Erythematosus | 0.5 | 0.7 | -0.4 |
Tic Disorder | 0.1 | 0.8 | -7 |
Tourette syndrome | 0.1 | -0.1 | |
Type 1 Diabetes | 0.3 | 1.4 | -3.67 |
Type 2 Diabetes | 1.3 | 1.9 | -0.46 |
Ulcerative colitis | 1 | 2.4 | -1.4 |
Unhealthy Ageing | 1.8 | 1.3 | 0.38 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.